3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Meet Veristat in Boston at DTRA
With nearly 30 years of experience in clinical trial planning and execution for complex cancer therapies, Veristat is equipped to support any development program.
If you are transitioning your compound into clinical trials, you need the right partner to guide your planning and decision-making. Whether you are preparing your IND/CTA, or you are looking to recruit patients quickly to get your early phase trials running, or just need medical writing or biostatistical support for your programs – Veristat can help.
As a versatile scientific CRO and consultancy, we provide impactful solutions on a full-service or functional service basis, integrating strategic planning, regulatory expertise, and clinical trial execution to rapidly advance the most complex or novel cancer therapies. In the past five years, Veristat has supported more than 300 oncology studies and we have worked on more than 30 US and European regulatory marketing applications for cancer treatments.
Schedule A Meeting
If you would like to meet with a member of our team, please contact us through the form to arrange a meeting.
We are…Bold. Scientific. Versatile. Veristat.
Conference Details
Website: https://www.dtra.org/dtra-2023-annual-meeting
Schedule A Meeting
Veristat team members Cindy Hendershot, Chief Strategy Officer, and Erin Gaffney, Senior Business Development Director, will be at the venue, ready to listen to your needs and share Veristat’s expertise.
Meet with us at DTRA 2023 by filling out the form below.
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...